KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Equity Average: 2011-2015

Historic Equity Average for Biocryst Pharmaceuticals (BCRX) over the last 4 years, with Sep 2015 value amounting to $70.1 million.

  • Biocryst Pharmaceuticals' Equity Average fell 19.25% to $70.1 million in Q3 2015 from the same period last year, while for Sep 2015 it was $70.1 million, marking a year-over-year decrease of 19.25%. This contributed to the annual value of $37.3 million for FY2014, which is 4815.76% up from last year.
  • According to the latest figures from Q3 2015, Biocryst Pharmaceuticals' Equity Average is $70.1 million, which was down 0.23% from $70.2 million recorded in Q2 2015.
  • In the past 5 years, Biocryst Pharmaceuticals' Equity Average ranged from a high of $86.8 million in Q3 2014 and a low of -$5.9 million during Q2 2013.
  • For the 3-year period, Biocryst Pharmaceuticals' Equity Average averaged around $36.9 million, with its median value being $42.2 million (2014).
  • As far as peak fluctuations go, Biocryst Pharmaceuticals' Equity Average crashed by 130.63% in 2013, and later surged by 6,865.37% in 2014.
  • Quarterly analysis of 5 years shows Biocryst Pharmaceuticals' Equity Average stood at $20.4 million in 2011, then slumped by 77.16% to $4.7 million in 2012, then crashed by 75.52% to $1.1 million in 2013, then soared by 6,865.37% to $79.5 million in 2014, then declined by 19.25% to $70.1 million in 2015.
  • Its Equity Average stands at $70.1 million for Q3 2015, versus $70.2 million for Q2 2015 and $70.0 million for Q1 2015.